Steroid-containing ophthalmic solutions more likely to be contaminated

Article

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free.

Ophthalmic solutions containing steroids are 5.8 times more likely to be contaminated with bacteria than solutions that are steroid-free, according to a report published in the October issue of the British Journal of Ophthalmology.

Danny H-Kauffmann Jokl and colleagues from the New York Medical College, New York, USA conducted a study to assess the frequency of ophthalmic solution contamination in a long-term care facility. A total of 123 solutions used for patient treatment were cultured for bacteria and the results were analysed according to the therapeutic class of the solution, how long the bottle was in use for and the appearance of the bottle upon visual inspection.

Ten (8%) of the solutions were contaminated with bacteria: four of eight steroid-containing anti-inflammatory solutions, two of six combination antimicrobial and steroid-containing anti-inflammatory solutions, two of 34 solutions for the treatment of glaucoma and two of 57 medications for dry eye. None of the mydriatic, miotic or non-combination antimicrobial solutions were found to be contaminated.

Just 30% of the contaminated bottles were considered "dirty" under visual inspection. Neither length of time that bottles had been in use or appearance of the bottles were found to be predictors of contamination.

The frequent contamination during reuse of certain steroid-containing ophthalmic solutions has led the research team to suggest that single-use solutions may be preferable.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.